S&P predicts modest growth for PPD; Oramed recruits Medpace for oral insulin trials;

> Looking at PPD, Standard & Poor's says the CRO's growth will be modest for the rest of the year, as escalating costs eat into profit. Story

> S. Eshwar Reddy, India's deputy drug controller, told in-PharmaTechnologist that India should not have to amend its good manufacturing practice laws to suit Western outsourcers. Article

> Laurantis Pharma has chosen Ark Therapeutics to manufacture and supply the lymphedema drug Lymfactin for Phase I trials. News

> Indian CRO Max Neeman International is expanding into Bangladesh, Sri Lanka and Malaysia to augment its operations in India, Europe and North America. More

> The FDA has called on investigators to include more children in clinical trials, but one expert says the industry is too wary of harming kids to follow through on the request. Item

> Oramed has signed on with CRO Medpace to conduct Phase II trials for ORMD-0801, the company's oral insulin capsule. Release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

WCG is continuing its buyout run after acquiring clinical trial solutions firm Trifecta Clinical.

London-based uMed has raised nearly $4.8 million from U.K. and U.S. VCs to help healthcare providers participate in more clinical studies.

Amgen has teamed up with cloud-based trial solutions firm Reify Health to help boost patients into its drug studies.